Immunotherapy
PD-L1 Inhibitor
Also known as: Anti-PD-L1, PD-L1 blocker
Definition
A type of immunotherapy that blocks the PD-L1 protein on cancer cells, preventing it from binding to PD-1 on immune cells.
Detailed Explanation
PD-L1 (Programmed Death-Ligand 1) is a protein expressed by cancer cells that binds to PD-1 on T cells, suppressing immune response. PD-L1 inhibitors like atezolizumab (Tecentriq) and durvalumab (Imfinzi) block this interaction from the ligand side, allowing the immune system to attack cancer cells.